NCT-05975073

A Phase 1/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, andEfficacy of AMG 193 in Combination With IDE397 in Subjects With Advanced MTAP-null SolidTumors

This is a Phase 1/2 study looking at whether a new drug called AMG 193, combined with another drug called IDE397, is safe and works well in people with advanced solid tumors that don't have a mutation in MTAP, an enyme that plays a role in DNA synthesis and repair.

Phase 1/2 study: A study that assesses the safety, effectiveness, and how well the treatment works

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05975073

Clinical Trial Site: Columbia

To see all available clinical trials click here.